Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.
ABSTRACT This study is a double-blind controlled trial in 86 patients of the efficacy of retention enemas containing 4 g 5-aminosalicylic acid (5-ASA), believed to be the active metabolite of sulphasalazine, compared with retention enemas of 100 mg of hydrocortisone for the topical treatment of mild or moderate ulcerative colitis. 5-ASA enemas given to 44 patients were significantly more effective than hydrocortisone enemas given to 42 patients, and produced 93, 93, and 77% remission in clinical, sigmoidoscopic, and histological terms, respectively, compared with corresponding remission rates of 57, 54, and 33% in the hydrocortisone treated patients.
- SourceAvailable from: Christoph Campregher
Article: Aminosalicylates[Show abstract] [Hide abstract]
ABSTRACT: Aminosalicylates are the most common drugs for the primary treatment of inflammatory bowel disease. Various pro-drugs and formulations were developed in order to improve pharmacological profiles, optimize bioavailability and to gain highest efficacy in the treatment of ulcerative colitis (UC) and Crohn's disease. In vitro studies have greatly contributed to the understanding of the molecular actions in vivo and clinical studies have proven aminosalicylates to be effective and safe. This review summarizes the current knowledge on the molecular, pharmacological and clinical properties of aminosalicylates with respect to chemoprevention for UC-associated colorectal cancer.Best practice & research. Clinical gastroenterology 08/2011; 25(4-5):535-46. DOI:10.1016/j.bpg.2011.10.013 · 3.28 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: In order to clarify the characteristics of absorption of 5-aminosalicylic acid (5-ASA) from the colon, a neutral solution was instilled into the right part of the colon and the rectum, respectively, in six volunteers. A laxative (bisacodyl) and liquid meals were given prior to each instillation. No significant difference could be demonstrated between the two parts of the large bowel, but the absorption was considerably restricted compared with previous results obtained from the jejunum. The results confirm in a direct manner earlier observations on 5-ASA released from sulphasalazine.British Journal of Clinical Pharmacology 03/1988; 25(2):269-72. DOI:10.1111/j.1365-2125.1988.tb03301.x · 3.69 Impact Factor
- Anesteziologiia i reanimatologiia